Shanghai Changzheng Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1955-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.shczyy.com
Clinical Trials
113
Active:2
Completed:11
Trial Phases
6 Phases
Early Phase 1:14
Phase 1:9
Phase 2:21
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (93 trials with phase data)• Click on a phase to view related trials
Not Applicable
35 (37.6%)Phase 2
21 (22.6%)Early Phase 1
14 (15.1%)Phase 4
13 (14.0%)Phase 1
9 (9.7%)Phase 3
1 (1.1%)Observational Study of Sacral Nerve Function After Sacral Tumor Resection
Not yet recruiting
- Conditions
- Sacral Tumors
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT07105644
- Locations
- 🇨🇳
Changzheng Hospital, Shanghai, Shanghai, China
Inhaled Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Post-Infectious Cough: A Single-Center Randomized Controlled Clinical Trial
Not Applicable
Recruiting
- Conditions
- Post-Infectious Cough
- Interventions
- Drug: Mesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine capsuleDrug: Normal saline nebulization combined with the compound methoxyphenamine capsule
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07103980
- Locations
- 🇨🇳
Shanghai changzheng hospital, Shanghai, Shanghai, China
A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
Not Applicable
Recruiting
- Conditions
- Colorectal Cancer MetastaticColorectal Cancer RecurrentColorectal Cancer Stage IV
- Interventions
- Drug: CD-GA-102
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT07050394
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, None Selected, China
Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens
Not yet recruiting
- Conditions
- Metabolic SyndromeDiabetesObesity and OverweightHypertensionDyslipidemiaThyroid DiseasesBone Metabolism DisorderChronic Kidney Disease(CKD)Cardiovascular Diseases (CVD)Cardiovascular-kidney-metabolic Syndrome
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 4094
- Registration Number
- NCT07043166
Evaluation of the Efficacy and Safety of Absorbable vs Traditional Bone Wax for Facet Fusion After Lumbar Fusion Surgery
Not Applicable
Not yet recruiting
- Conditions
- Lumbar Fusion SurgeryFusion of Joint
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 330
- Registration Number
- NCT07040293
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 22
- Next
News
First-in-Human iPSC-CAR-NK Cell Therapy Shows Promise for Autoimmune Disease Treatment
Qihan Biotech's QN-139b represents the first-ever application of iPSC-CAR-NK cells in treating autoimmune disease, successfully inducing immune reset in a patient with refractory systemic sclerosis.